Search

Your search keyword '"Tatiana Tzenou"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Tatiana Tzenou" Remove constraint Author: "Tatiana Tzenou"
70 results on '"Tatiana Tzenou"'

Search Results

1. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

2. Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

3. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

4. Figure S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

5. Data from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

6. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

7. Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia

8. MANTLE CELL LYMPHOMA, A SINGLE CENTER EXPERIENCE

9. Chimeric Antigen Receptor T Cells for Refractory/Relapsed Diffuse Large B Cell Lymphoma and Acute Lymphoblastic Leukemia: The Hellenic Real-World Experience in Adult Patients

10. Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

11. Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation: Increased Incidence in Association with Immune Reconstitution

12. No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

13. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

14. Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course

15. The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features

16. Increased Incidence of Viral Reactivation after T Cell Replete Haploidentical Stem Cell Transplantation in Association with Delayed Immune Reconstitution

17. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2

18. Prognostic Contribution of the New Immunoglobulin (Ig) Biomarkers (Freelite™ and Hevylite™) in Waldenstrom’s Macroglobulinemia (WM)

19. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

20. CD138 Expression Helps Distinguishing Waldenström's Macroglobulinemia (WM) From Splenic Marginal Zone Lymphoma (SMZL)

21. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

22. Validation of Frailty Assessment in Multiple Myeloma (MM) Patients

23. Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score

24. Clonotypic Analysis of Immunoglobulin Heavy Chain Sequences in Patients with Waldenström’s Macroglobulinemia: Correlation with MYD88 L265P Somatic Mutation Status, Clinical Features, and Outcome

25. Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia

26. Prognostic Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia

27. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse

28. Chapter 8 The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients

29. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

30. Study of MGUS-Series: Disease Evolution, Coexistant Disorders and Other Clinical Observations

31. CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference

32. Mutation analysis of IgVH genes in splenic marginal zone lymphomas: correlation with clinical characteristics and outcome

33. Staging systems and prognostic factors as a guide to therapeutic decisions in multiple myeloma

34. Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients

35. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib

36. Serum levels of soluble syndecan-1 in Hodgkin's lymphoma

37. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders

38. Chapter 8 The Contribution of Prognostic Factors to the Better Management of Multiple Myeloma Patients

39. Evaluation Of Immunoglobulin Variations (Clonal Changes) In Symptomatic Multiple Myeloma (MM) Patients’ Course

40. Clonotypic Analysis Of Immunoglobulin Heavy Chain (IgH) Sequences In Patients With Waldenström’s Macroglobulinemia. Correlation With MYD88 L265P Somatic Mutation Status, Clinical Features and Outcome

41. The Presence Of Spine Bone Plasmacytomas At The Time Of Multiple Myeloma (MM) Diagnosis Confers Poor Prognosis

42. Contribution of new immunoglobulin-derived biomarkers in plasma cell dyscrasias and lymphoproliferative disorders

43. Increased Serum Transforming Growth Factor-beta1 (Tgf-beta1) Is Related to a Better Outcome in MM, WM and CLL Patients

44. A Shorter Time to First Treatment and Worst Overall survival Is Observed in Cll Patients with Reduced Serum IgM As Evaluated with Novel Serum Immunoassays

45. Significance of Serum Free Light Chains in Chronic Lymphocytic Leukemia (cll) Prognosis

46. Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma

47. Heavy Chain Ratio (HLCR) IgGκ/IgGλ or IgAκ/IgAλ: Experience and Clinical Implications In Multiple Myeloma at Diagnosis and During Disease Course

48. Quantification of Serum IgMκ and IgMλ In Patients with Waldenstrom's Macroglobulinemia (WM) at Diagnosis and During Disease Course; Clinical Correlations

49. Genetic and molecular mechanisms in multiple myeloma: a route to better understand disease pathogenesis and heterogeneity

50. Increased Immunohistochemical CD138 Expression in Waldenström's Macroglobulinemia (WM) in Comparison with Splenic Marginal Zone Lymphoma (SMZL)

Catalog

Books, media, physical & digital resources